Rally Foundation
-
A new target for neuroblastoma
Vanderbilt investigators have discovered that a sirtuin protein has oncogenic properties in neuroblastoma cells — and that blocking it reduces their growth and tumor-like characteristics. Read MoreFeb 14, 2018
-
Boosting sarcoma cell death
A compound identified at Vanderbilt represents a new lead for treating rare, aggressive childhood cancers called Ewing sarcomas. Read MoreOct 4, 2017
-
Blocking neuroblastoma cell growth
An inhibitor of cell metabolism may be a good therapeutic target for neuroblastoma, which accounts for about 15 percent of pediatric cancer-related deaths. Read MoreMar 22, 2017
-
Proliferative capacity of neuroblastoma
The sphere-forming frequency of neuroblastoma cells is a measure of their proliferative capacity and could help guide treatment strategies for neuroblastoma. Read MoreAug 31, 2016
-
Rally for Kids with Cancer
Actor and retired professional basketball player Rick Fox (sitting to the left of mascot Champ) poses for a photo with his scavenger hunt team, Cancer Crushers, at Monroe Carell Jr. Children’s Hospital at Vanderbilt on Oct. 3. The Cancer Crushers participated in and won the second annual Rally for Kids with Cancer, which raises funds for pediatric cancer research, treatment and care at Children’s Hospital and the Rally Foundation. Read MoreOct 8, 2015
-
Grant to support neuroblastoma research
The Rally Foundation awarded an $80,000 grant to the Monroe Carell Jr. Children’s Hospital at Vanderbilt to fund a research study on the treatment of neuroblastoma. Read MoreJun 24, 2011